



June 06, 2018

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sirs,

Sub : **Intimation of Schedule of Investor Meetings**
Stock Code : **BSE – 539787, NSE - HCG**
Ref : **Regulation 30(6) read with Schedule III Part A Para A (15) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the above cited regulation(s) and other applicable provisions, we would like to inform you that the representatives of the Company have concluded meetings with the investors/funds/analysts as detailed below on June 5, 2018 at B&K's Annual Investor Conference TRINITY India.

Sl. No.	Names of investors/funds/analysts
1.	Pabrai Funds
2.	Sloane Robinson
3.	ICICI Prudential MF
4.	Alchemy Capital
5.	Amiral Gestion
6.	Anvil
7.	Avendus Capital
8.	Ellara Capital
9.	HDFC Standard Life
10.	Kotak Mutual Fund
11.	L&T Mutual Fund
12.	Mahindra AMC
13.	Max Life
14.	Polunin Capital Partners

The Investors/Analyst/Funds were briefed on the general business overview and financial highlights of the Company for the year ended 31 March 2018 as per the earnings presentation, sent to the Stock Exchanges vide our letter dated 22 May 2018 and uploaded on the Company's website with the link <https://hcgel.com/investors>.

Please note that the Investors/Funds/Analysts may also subsequently approach the Company, for any clarifications regarding the discussions they had during the aforesaid meeting.

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,

For **HealthCare Global Enterprises Limited**

SUNU MANUEL Digitally signed by SUNU MANUEL
Date: 2018.06.06 20:01:48 +05'30'

Sunu Manuel
Company Secretary and Compliance Officer

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



The Specialist
in Cancer Care

adding life to years

June 06, 2018

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sirs,

Sub : Intimation of Schedule of Investor Meetings

Stock Code : BSE – 539787, NSE - HCG

Ref : Regulation 30(6) read with Schedule III Part A Para A (15) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited regulation(s) and other applicable provisions, we would like to inform you that the representatives of the Company have concluded meetings with the investors/funds/analysts as detailed below on June 5, 2018 at B&K's Annual Investor Conference TRINITY India.

Sl. No.	Names of investors/funds/analysts
1.	Pabrai Funds
2.	Sloane Robinson
3.	ICICI Prudential MF
4.	Alchemy Capital
5.	Amiral Gestion
6.	Anvil
7.	Avendus Capital
8.	Ellara Capital
9.	HDFC Standard Life
10.	Kotak Mutual Fund
11.	L&T Mutual Fund
12.	Mahindra AMC
13.	Max Life
14.	Polunin Capital Partners

The Investors/Analyst/Funds were briefed on the general business overview and financial highlights of the Company for the year ended 31 March 2018 as per the earnings presentation, sent to the Stock Exchanges vide our letter dated 22 May 2018 and uploaded on the Company's website with the link <https://hcgel.com/investors>.

Please note that the Investors/Funds/Analysts may also subsequently approach the Company, for any clarifications regarding the discussions they had during the aforesaid meeting.

Kindly take this on record and acknowledge receipt of this intimation.

Thanking you,

For **HealthCare Global Enterprises Limited**

Sunu Manuel
Company Secretary and Compliance Officer



HealthCare Global Enterprises Ltd.

HCG Tower #8, P. Kalinga Rao Road, Sampangi Ram Nagar, Bangalore - 560 027.

91 80 3366 9999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489